Effect of CpG oligonucleotides on vaccine-induced B cell memory

Journal of Immunology

Volumn 181, Issue 8, 2008, Pages 5785-5790

  Tross, Debra ^a   Klinman, Dennis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BACTERIUM ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; CELL EXPANSION; CONTROLLED STUDY; FEMALE; IMMUNOSTIMULATION; INFECTION RESISTANCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; MOUSE; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PRIORITY JOURNAL; PROVOCATION TEST; SURVIVAL RATE; ANIMAL; B LYMPHOCYTE; DRUG EFFECT; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PATHOLOGY; TIME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODY FORMATION; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MICE; OLIGODEOXYRIBONUCLEOTIDES; TIME FACTORS;

EID: 54049105664     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.8.5785     Document Type: Article

References (39)

1. Hanna, P. 1998. Anthrax pathogenesis and host response. Curr. Top. Microbiol. Immunol. 225: 13-35.
2. Chowdhury, K., S. E. Light, C. F. Garon, Y. Ito, and M. A. Israel. 1980. A cloned polyoma DNA fragment representing the 5′ half of the early gene region is oncogenic. J. Virol. 36: 566-574. (Pubitemid 10029390)
3. Little, S. F., and B. E. Ivins. 1999. Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect. 1: 131-139.
4. Welkos, S., S. Little, A. Friedlander, D. Fritz, and P. Fellows. 2001. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147: 1677-1685. (Pubitemid 32544833)
5. Welkos, S. L., and A. M. Friedlander. 1988. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 5: 127-139.
6. Friedlander, A. M., and P. S. Brachman. 1998. Anthrax. In Vaccines. S. A. Plotkin and E. A. Mortimer, eds. W. B. Saunders, Philadelphia, p. 729.
7. Ivins, B. E., and S. L. Welkos. 1988. Recent advances in the development of an improved, human anthrax vaccine. Eur. J. Epidemiol. 4: 12-19. (Pubitemid 18100281)
8. Pittman, P. R., P. H. Gibbs, T. L. Cannon, and A. M. Friedlander. 2001. Anthrax vaccine: short-term safety experience in humans. Vaccine 20: 972-978.
9. Brachman, P. S., H. Gold, S. A. Plotkin, F. R. Fedety, M. Werrin, and N. R. Ingraham. 1962. Field evaluation of a human anthrax vaccine. Am. J. Public Health Nations Health 52: 632-645.
10. Ready, T. 2004. US soldiers refuse to fall in line with anthrax vaccination scheme. Nat. Med. 10: 112. (Pubitemid 38524869)
11. Geier, D. A., and M. R. Geier. 2002. Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios. Clin. Exp. Rheumatol. 20: 217-220.
12. Lane, H. C., J. L. Montagne, and A. S. Fauci. 2001. Bioterrorism: a clear and present danger. Nat. Med. 7: 1271-1273.
13. Xie, H., I. Gursel, B. E. Ivins, M. Singh, D. T. O'Hagan, J. B. Ulmer, and D. M. Klinman. 2005. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun. 73: 828-833. (Pubitemid 40165739)
14. Klinman, D. M., D. Currie, G. Lee, V. Grippe, and T. Merkel. 2007. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microbes Infect. 9: 1478-1483.
15. Klinman, D. M., H. Xie, and B. E. Ivins. 2006. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann. NY Acad. Sci. 1082: 137-150. (Pubitemid 44955459)
16. Krieg, A. M., A. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-548.
17. Klinman, D. M., A. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12, and IFNg. Proc. Natl. Acad. Sci. USA 93: 2879-2883.
18. Takeshita, F., C. A. Leifer, I. Gursel, K. Ishii, S. Takeshita, M. Gursel, and D. M. Klinman. 2001. Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167: 3555-3558. (Pubitemid 32910795)
19. Hemmi, H., O. Takeuchi, T. Kawai, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745. (Pubitemid 32015992)
20. Ballas, Z. D., W. L. Rasmussen, and A. M. Krieg. 1996. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157: 1840-1847.
21. Halpern, M. D., R. J. Kurlander, and D. S. Pisetsky. 1996. Bacterial DNA induces murine interferon-γ production by stimulation of IL-12 and tumor necrosis factor-α. Cell. Immunol. 167: 72-78. (Pubitemid 26048848)
22. Ivins, B. E., M. L. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, Jr., P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16: 1141-1148.
23. Ivins, B. E., S. L. Welkos, G. B. Knudson, and S. F. Little. 1990. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 58: 303-308.
24. Harvill, E. T., G. Lee, V. K. Grippe, and T. J. Merkel. 2005. Complement depletion renders C57BL/6 mice sensitive to the Bacillus anthracis Sterne strain. Infect. Immun. 73: 4420-4422.
25. Klinman, D. M., H. Xie, S. F. Little, D. Currie, and B. E. Ivins. 2004. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22: 2881-2886.
26. Rynkiewicz, D., M. Rathkopf, J. Ransom, I. Sim, L. Giri, J. Quinn, T. Waytes, M. Al-Adhami, W. Johnson, and C. Nielsen. 2005. Marked enhancement of antibody response to anthrax vaccine adsorbed with CpG 7909 in healthy volunteers. In Interscience Conference on Antimicrobial Agents and Chemotherapy, p. LB-25 (Abstr.).
27. Klinman, N. R. 1972. The mechanism of antigenic stimulation of primary and secondary clonal precursor cells. J. Exp. Med. 136: 241-260.
28. Klinman, N. R., and G. Aschinazi. 1971. The stimulation of splenic foci in vitro. J. Immunol. 106: 1338-1344.
29. Riley, R. L., and N. R. Klinman. 1986. The affinity threshold for antigenic triggering differs for tolerance susceptible immature precursors vs mature primary B cells. J. Immunol. 136: 3147-3154.
30. Eggers, M., U. Bader, and G. Enders. 2000. Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy. J. Med. Virol. 60: 324-330. (Pubitemid 30054287)
31. Cozon, G. J., J. Ferrandiz, H. Nebhi, M. Wallon, and F. Peyron. 1998. Estimation of the avidity of immunoglobulin G for routine diagnosis of chronic Toxoplasma gondii infection in pregnant women. Eur. J. Clin. Microbiol. Infect. Dis. 17: 32-36.
32. Klinman, D. M., D. Currie, I. Gursel, and D. Verthelyi. 2004. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199: 201-216. (Pubitemid 38736773)
33. Klinman, D. M. 2006. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol. 25: 135-154.
34. Sparwasser, T., E. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W. Ellwart, and H. Wager. 1998. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28: 2045-2054. (Pubitemid 28271721)
35. Gursel, M., D. Verthelyi, and D. M. Klinman. 2002. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur. J. Immunol. 32: 2617-2622.
36. Weiss, S., D. Kobiler, H. Levy, H. Marcus, A. Pass, N. Rothschild, and Z. Altboum. 2006. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect. Immun. 74: 394-398. (Pubitemid 43023096)
37. Reuveny, S., M. D. White, Y. Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69: 2888-2893. (Pubitemid 32332179)
38. Little, S. F., B. E. Ivins, P. F. Fellows, M. L. Pitt, S. L. Norris, and G. P. Andrews. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22: 422-430.
39. Ivins, B. E., P. F. Fellows, M. L. M. Pitt, J. E. Estep, S. L. Welkos, and P. L. F. A. Worsham. 1985. Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Med. Bull. 87: 125-126.